Cabinet Bans Puberty Blockers Despite Health Advice, High Court Reacts

The government has enacted a ban on new prescriptions for puberty blockers aimed at treating gender dysphoria, despite clear advice from the Ministry of Health urging against such a move. Newly released documents indicate that ministers disregarded health officials’ recommendations, which suggested maintaining the current approach was the most prudent option. This decision has prompted the High Court to express concerns, indicating a perception that the ban may have been influenced by political motives.

The ban, which took effect on Friday, was met with immediate pushback from the High Court, which issued an order on Wednesday to suspend its enforcement until a more comprehensive legal argument can be presented in 2024. The court’s findings highlighted that the Cabinet’s position did not align with the medical guidance provided in the Regulatory Impact Statement (RIS).

In a detailed review, the Ministry of Health had previously published a position statement and evidence review concerning the prescription of puberty blockers. This assessment found insufficient robust evidence to support either the claimed benefits for mental health or the purported negative effects of the medication. The ministry advised that medical professionals should communicate the lack of evidence to patients when considering treatment options.

Despite these findings, Minister of Mental Health Matt Doocey and former Health Minister Shane Reti advocated for regulatory measures to restrict new prescriptions. Earlier this year, a proposal was consulted upon, but little action followed until Health Minister Simeon Brown announced the ban last month.

The documents released late on Thursday illustrate that health officials had developed multiple options for Cabinet deliberation. Brown presented four pathways: maintaining the status quo, enhancing monitoring by the Ministry of Health, implementing regulations to restrict new prescriptions while expanding gender care services, or enforcing a complete ban. The Cabinet ultimately chose the third option, which Brown indicated would be reviewed after a scientific trial in the United Kingdom that is set to begin soon.

Officials’ advice accompanying the Cabinet paper indicated a preference for either maintaining the status quo or enhancing monitoring. They stated, “There is no option that we can definitively say advances our objectives,” emphasizing that the status quo would allow clinicians to assess risks and benefits tailored to individual patients. The ministry’s position statement aimed to ensure access to treatments while protecting against potential harm.

By contrast, the regulated ban was deemed to offer fewer advantages and could hinder practitioners’ abilities to make decisions in the best interest of their patients. The officials warned that restricting access could lead some young individuals to seek puberty blockers through unsafe online channels, risking their health.

A child impact assessment noted that options limiting access to puberty blockers beyond the current framework could negatively affect young people with gender-related health needs. The assessment did not support such restrictions from a child-centered perspective.

The Cabinet paper did not clearly communicate the Ministry of Health’s opposition to the other options presented. Additionally, it failed to mention that the UK scientific trial could extend until 2031, suggesting that the ban may not be a temporary measure.

Following the Cabinet’s decision, the Ministry of Health and Health NZ developed three options for expanding gender care services: establishing a national center of excellence, creating four regional hubs, or implementing a locally driven model with district hubs. A subsequent paper submitted to Cabinet included a fourth option—developing an online resource page that would require no additional funding but would likely have minimal impact on improving access to youth gender services.

Ultimately, the Cabinet chose the online resource option, which means the anticipated benefits from enhanced service provision may not materialize. When questioned about the rationale for overriding health advice, Minister Simeon Brown maintained that the government stands by its decision to restrict prescriptions for new patients seeking treatment for gender dysphoria and is currently seeking legal counsel regarding the next steps.

The implications of this decision resonate widely, as it affects the health and well-being of young individuals navigating gender dysphoria, raising significant concerns among health professionals and advocates alike.